Crocodile Gold CEO Says a Focus on Value over Ounces Will Boost Prospects in 2014
Source: Dan Lonkevich of The Gold Report   (11/20/13)
After posting record production and recovery rates at its three mines in Australia and significantly raising its production guidance for the year, Crocodile Gold Corp. may be poised for an even better 2014. Thanks to a quickening ramp-up of its early-stage Cosmo mine, its new Big Hill project and noncore asset divestiture plans, Crocodile CEO Rodney Lamond tells The Gold Report that his company has ample funding and the proper focus on value over ounces to succeed even in today's challenging pricing environment. More >

Understanding High-Grade Lump Graphite
Source: J. Alec Gimurtu of The Gold Report  (11/18/13)
Four graphite ore samples are placed on a conference room table. Straight from the earth, which one can be used to write on a piece of paper? Answer: the lump graphite sample. In this interview with The Gold Report, Paul Ogilvie, CEO of the newly formed Saint Jean Carbon, explains the distinctive advantages of lump graphite from a mining and marketing perspective and describes his plan to create a profitable company from an uncommon form of high-grade graphite deposit. Read how the company is educating investors on this highest-grade form of graphite while restarting world-class mines using modern technology and an experienced business team.
More >

Comstock Mining CEO: Goal of Doubling Production in 2014 Just First Step
Source: JT Long of The Gold Report  (11/13/13)
Comstock Mining Inc. is set to double its gold production to 40,000 oz in 2014 and may soon be able to boost production nearly fourfold. In this interview with
The Gold Report, Comstock Mining CEO Corrado De Gasperis explains why the company's sizeable resource potential, successful permitting achievements, low-cost drilling program and cultural commitment to safety and environmental responsibility are just a few of the reasons why investors should be following this attractive gold producer.
More >

Sulliden Gold's Low-Cost Shahuindo Project Validated by Agnico-Eagle Investment
Source: Dan Lonkevich of The Gold Report  (11/1/13)
Sulliden Gold Corporation Ltd.'s Shahuindo gold project in Peru was validated as a low-cost, high-return project by a strategic investment of $24 million by Agnico-Eagle Mines Ltd. last April. Sulliden's president and director, Justin Reid, tells The Gold Report about the factors that have led to the company being one of the top performing mining stocks on the Toronto Stock Exchange this year. Sulliden has a balance sheet of $70 million, including a recently completed $40 million bought-deal financing, and Reid says the company is close to finalizing the funding package needed to complete the construction phase of the project in 2014 and begin the first full year of production in 2015. More >

Muscling into the Nutritional Supplements Market: Brad Pyatt
Source: George S. Mack of The Life Sciences Report  (9/26/13)
Sports analogies are used way too often in business, but MusclePharm Corp.'s Founder, President and CEO Brad Pyatt has used his experience as a wide receiver in the National Football League to build a nutritional supplement business, employing leadership tools he learned from great coaches and players. In this interview with The Life Sciences Report, Pyatt talks about his young company's explosive growth, and how he expects to continue expanding both revenue and earnings to generate tremendous shareholder value. More >

Provectus Pharmaceuticals Inc. and PV-10: Rose Bengal as a Novel Cancer Therapeutic
Source: Daniel Levy of The Life Sciences Report  (9/19/13)
Despite all of the advances in diagnosis and treatment, the family of diseases that falls under the umbrella of "cancer" still represents a significant unmet medical need. Consequently, research continues in the discovery and development of therapeutic agents with novel mechanisms of action, wider therapeutic indexes and lower overall toxicities. In this interview with The Life Sciences Report, Peter Culpepper, CFO and COO of Provectus Pharmaceuticals Inc., describes his company's innovative rose bengal formulation and its use as a cancer therapeutic. More >

Pro-Or Seizes Market Opportunity with Platinum Recycling Technology
Source: J. Alec Gimurtu of The Metals Report  (9/18/13)
The largest end-use application for platinum group metals, automotive catalytic converters, is also North America's largest potential source. Every year, nearly 15 million North American cars expire—and recycling the platinum group metals within them is far cheaper than building a three-mile mine shaft in a faraway country. In this interview with The Metals Report, Sylvain Boulanger, CEO of Pro-Or Inc., describes how his company's technology improves recoveries, simplifies the supply chain and reduces costs. More >

Peruvian Precious Metals Repeating a Winning Formula
Source: Alec Gimurtu of The Gold Report   (9/4/13)
The management team that took Prodigy Gold from a $25 million market cap junior to a $340 million buyout in less than three years is back with a new company that it believes is tailor made for applying its formula for success. In this interview with The Gold Report, CEO Brian Maher and VP of Corporate Development Kimberly Ann discuss their latest project, how they are "managing through change" and what differentiates them in an industry of over-promoting and under-delivering juniors. Clear communication is part of the formula, but there is more than talk when it comes to advancing a great project in South America's largest gold producing region. More >

Mesoblast Ltd. Targets Success in the Degenerative Disc Space
Source: George S. Mack of The Life Sciences Report  (7/25/13)
The biggest challenge in the treatment of degenerative disc disease lies in the inhospitable nature of the intervertebral space, where the blood flow and nutrients necessary to cell survival are in short supply. Mesoblast Ltd. has developed a cell therapy that addresses that challenge, triggering the regenerative qualities of surrounding cells to promote healing. In this interview with The Life Sciences Report, Mesoblast Founder, CEO and Managing Director Silviu Itescu describes the science that promises relief to millions of back pain sufferers. More >

BioRestorative Therapies Inc. Develops Plug-and-Play Therapy for Bulging/Herniated Disc Disease
Source: George S. Mack of The Life Sciences Report  (7/25/13)

Millions of people suffer back pain caused by herniated and bulging disc disease. When conventional medical therapies fail they often resort to surgery for relief, a costly and time-consuming solution for both patients and the medical system. In this interview with The Life Sciences Report, Mark Weinreb, president, CEO and chairman of BioRestorative Therapies Inc., describes how his company's cell therapy process could keep disc disease treatment out of the operating theater.